Hims & Hers Health, Inc. (HIMS)

NYSE • Healthcare

$27.71

-$1.41 (-4.9%)

Market closed

October 23, 2026 at 20:00 UTC

Open$28.85

Day Range$27.3 - $28.91

Avg. Volume (3M)9.9M

Market Cap$6.2B

52 Week Range

$13.74$50.19

Next EarningsIn 15 daysNov 9, 2026

12H

All

20:52:15 UTC

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$753.2M100%

Gross Profitminus cost of goods$480.8M64%

In plain terms: out of every $100 in revenue, Hims & Hers Health, Inc. currently loses $11.

Fundamentals & Financials

Revenue (TTM)

$2.5B

Net Income (TTM)

-$142M

EPS (TTM)

-$0.61

ROA (TTM)

-3.91%

Current Ratio

0.93

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-5.6%Q3 2025$0.17

-33.3%Q4 2025$0.06

+250.0%Q1 2026$0.07

-1676.7%Q2 2026-$0.4

-643.1%Q3 2026-$0.37

Nov 9

in 15 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -643.1%

Hims & Hers Health beat revenue consensus in the second fiscal quarter of 2026, based on preliminary results reported Aug. 10, as revenue rose about 38% to roughly $753.2 million from about $544.8 million a year ago and came in about 8% above the $698.9 million estimate. Gross profit reached about $577.3 million, with gross margin near 77%, while operating cash flow was negative $35.9 million. Consensus for the next period calls for EPS of $0.12 on revenue of $792.2 million.

Next report — what to expect

Hims & Hers Health Inc (HIMS) reports next on November 9, 2026. Wall Street is looking for EPS of $0.057 on revenue of $892.9 million. For trailing context, revenue grew +38.2% year over year last quarter. The company has beaten EPS in 4 of its 8 most recent quarters.

View full earnings history

About Hims & Hers Health, Inc.

Hims & Hers Health, Inc. (NYSE: HIMS) provides consumer-focused healthcare products and services across prescription and nonprescription categories, operating in healthcare with an emphasis on medical products, related services, and digital access. The company generated $2.3 billion in FY2025 revenue.

Name

Hims & Hers Health, Inc.

CEO

Andrew Dudum

Website

www.hims.com

Industry

Healthcare

Year Founded

2017

Employees

2,442

Today's Snapshot

AI-generated

HIMS closed 4.9% below yesterday's close, in line with a weaker sector. Hims & Hers Health faces a securities class-action lawsuit from investors.

Trading Volume

Below 10d avg (9.9M)

9.8M

vs S&P 500 Today

Strong Underperformance

-4.35%

Updated: October 23, 2026 at 20:20 UTC

HIMS Headlines

Hims & Hers moves to dismiss FTC lawsuit

October 22, 2026

4 min read

FTC sues telehealth firm Hims & Hers

July 29, 2026

3 min read

Hims & Hers Plunges on Wegovy Copycat Fallout

February 9, 2026

4 min read

Hims–Novo Nordisk clash over new weight-loss pill

February 7, 2026

3 min read

View All News

Technical Indicators

0 Buy2 Neutral6 Sell

HIMS at about $27.71 shows multiple short-term momentum and moving-average sell signals that underpin the strong-sell rating. The MACD and CCI are negative and momentum is falling, while most short- and medium-term moving averages lie above the current price; the 200-day average is an exception but is only marginally below price. Volume on balance is negative and volatility is elevated with an ATR near 6.6%, which amplifies downside risk. ADX indicates a weak trend overall. Technical takeaway: Strong Sell.

All signals